A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

Table 2 Adverse events (safety population)

	Placebo b.i.d. (n = 3)	Placebo t.i.d. (n = 15)	Placebo total (n = 18)	GSK2982772 60 mg b.i.d. (n = 5)	GSK2982772 60 mg t.i.d. (n = 28)	GSK2982772 60 mg total (n = 33)
Any AE, n (%)	3 (100)	10 (67)	13 (72)	3 (60)	17 (61)	20 (61)
Any SAE, n (%)	0	0	0	0	2 (7)	2 (6)
Eye disorder
Retinal vein thrombosis	0	0	0	0	1 (4)	1 (3)
Injury, poisoning and procedural complications
Multiple fractures	0	0	0	0	1 (4)	1 (3)
Any AE leading to withdrawal, n (%)	0	0	0	0	3 (11)	3 (9)
Infections and infestations
Bronchitis	0	0	0	0	1 (4)	1 (3)
Eye disorder
Retinal vein thrombosis (SAE)	0	0	0	0	1 (4)	1 (3)
Injury, poisoning, and procedural complications
Multiple fractures (SAE)	0	0	0	0	1 (4)	1 (3)
Any treatment-related AEs, n (%)	3 (100)	2 (13)	5 (28)	1 (20)	6 (21)	7 (21)
Severe	0	0	0	0	1 (4)	1 (3)
Moderate	1 (33)	1 (7)	2 (11)	1 (20)	4 (14)	5 (15)
Mild	2 (67)	1 (7)	3 (17)	0	1 (4)	1 (3)
AEs occurring in > 10% of combined groups, n (%)
Musculoskeletal and connective tissue disorders
Arthralgia			2 (11)			2 (6)
Nervous system disorders
Headache			2 (11)			1 (3)
General disorders and administration site conditions
Peripheral swelling^a			2 (11)			0

^aIncluded swelling in the lower limbs and hands
AE, adverse event; b.i.d., twice daily; SAE, serious adverse event; t.i.d., three times daily

ISSN: 1478-6362